类有机物
药品
毒品检测
计算生物学
医学
计算机科学
病理
生物
药理学
化学
神经科学
色谱法
作者
Camilla Calandrini,Jarno Drost
出处
期刊:STAR protocols
[Elsevier]
日期:2022-03-01
卷期号:3 (1): 101079-101079
被引量:10
标识
DOI:10.1016/j.xpro.2021.101079
摘要
Patient-derived tumor organoids can be predictive of patient's treatment responses, and normal tissue-derived organoids allow for drug toxicity testing. Combining both types of organoids therefore enables screening for tumor-specific drug vulnerabilities. Here, we provide a detailed protocol for organoid drug screening using, as proof-of-principle, patient-derived malignant rhabdoid tumor organoids. The protocol can be adapted for drug testing on any tumor and/or normal tissue-derived organoid culture. For complete details on the use and execution of this protocol, please refer to Calandrini et al. (2021).
科研通智能强力驱动
Strongly Powered by AbleSci AI